Table 2.
Inhibitory effects of purified compounds on superoxide anion generation and elastase release by human neutrophils in response to fMLF/CB.
| Compound | Superoxide Anion Generation | Elastase Release | ||
|---|---|---|---|---|
| IC50 (μM) a | Inh % b | IC50 (μM) | Inh % | |
| 45 | 6.4 ± 0.7 | 70.5 ± 6.8 *** | – c | 34.2 ± 6.9 ** |
| 47 | 6.0 ± 1.1 | 71.8 ± 8.1 *** | – | 43.5 ± 6.9 *** |
| 48 | 3.3 ± 0.9 | 87.5 ± 5.4 *** | 5.3 ± 0.2 | 93.9 ± 5.2 *** |
| 49 | 7.7 ± 0.9 | 60.6 ± 3.9 *** | – | 40.3 ± 6.0 ** |
| 50 | 5.3 ± 1.1 | 72.9 ± 6.3 *** | 5.8 ± 0.9 | 81.4 ± 12.0 *** |
| 51 | – | 45.2 ± 5.6 *** | 8.3 ± 0.8 | 57.0 ± 4.6 *** |
| LY294002 d | 1.1 ± 0.3 | 100.6 ± 1.0 *** | 3.2 ± 1.0 | 76.7 ± 6.8 *** |
Results are presented as mean ± SEM (n = 3-5). ** p < 0.01, *** p < 0.001 compared with the control (DMSO). a Concentration necessary for 50% inhibition (IC50). b Percentage of inhibition (Inh %) at 10 μM concentration. c Not determined. d A phosphatidylinositol-3-kinase inhibitor was used as a positive control.